Invirsa’s lead compound, INV-102, is derived from a naturally occurring small molecule that modulates the activity of three parallel enzyme systems that are critical to innate immune response. In vitro tests have already shown that INV-102 significantly reduces plaque formation caused by adenovirus (the main virus associated with infectious conjunctivitis). Reduced plaque indicates that there is less cellular injury and death caused by the virus.
Dr. Shalwitz is a pediatric endocrinologist with extensive background in clinical research and experience with the FDA. He has led teams to multiple successful new and supplemental drug approvals (NDAs and sNDAs) while at Abbott Laboratories and Reliant Pharmaceuticals. As one of the founders of both Akebia Therapeutics and Aerpio Therapeutics, Dr. Shalwitz participated in raising over $200 Million, including a successful public offering of Akebia.
Have a question? Partnerships? We’re always open to talking. Send us a message at firstname.lastname@example.org or fill out the form below.